These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 25673546)

  • 1. RISUG: an intravasal injectable male contraceptive.
    Lohiya NK; Alam I; Hussain M; Khan SR; Ansari AS
    Indian J Med Res; 2014 Nov; 140 Suppl(Suppl 1):S63-72. PubMed ID: 25673546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relative suitability of DMSO and NaHCO3 for reversal of RISUG® induced long-term contraception.
    Ansari AS; Hussain M; Khan SR; Lohiya NK
    Andrology; 2016 Mar; 4(2):306-13. PubMed ID: 26748683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RISUG (reversible inhibition of sperm under guidance)--an antimicrobial as male vas deferens implant for HIV free semen.
    Guha SK
    Med Hypotheses; 2005; 65(1):61-4. PubMed ID: 15893119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety & efficacy of an intravasal, one-time injectable & non-hormonal male contraceptive (RISUG): A clinical experience.
    Sharma RS; Mathur AK; Singh R; Das HC; Singh GJ; Toor DPS; Guha SK
    Indian J Med Res; 2019 Jul; 150(1):81-86. PubMed ID: 31571633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A proton NMR study of the effect of a new intravasal injectable male contraceptive RISUG on seminal plasma metabolites.
    Sharma U; Chaudhury K; Jagannathan NR; Guha SK
    Reproduction; 2001 Sep; 122(3):431-6. PubMed ID: 11597307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II clinical trial of a vas deferens injectable contraceptive for the male.
    Guha SK; Singh G; Ansari S; Kumar S; Srivastava A; Koul V; Das HC; Malhotra RL; Das SK
    Contraception; 1997 Oct; 56(4):245-50. PubMed ID: 9408706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversibility with sodium bicarbonate of styrene maleic anhydride, an intravasal injectable contraceptive, in male rats.
    Koul V; Srivastav A; Guha SK
    Contraception; 1998 Oct; 58(4):227-31. PubMed ID: 9866004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perspectives of contraceptive choices for men.
    Lohiya NK; Manivannan B; Bhande SS; Panneerdoss S; Garg S
    Indian J Exp Biol; 2005 Nov; 43(11):1042-7. PubMed ID: 16313067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intra-vas deferens injection of styrene maleic anhydride gel for male contraception: is it safe?
    Singh AK
    J Fam Plann Reprod Health Care; 2002 Oct; 28(4):208-9. PubMed ID: 12419065
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluation of genotoxicity in leukocytes and testis following intra-vasal contraception with RISUG and its reversal by DMSO and NaHCO₃ in Wistar albino rats.
    Ansari AS; Alam I; Hussain M; Khan SR; Lohiya NK
    Reprod Toxicol; 2013 Apr; 36():53-9. PubMed ID: 23246611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contraception with RISUG
    Ansari AS; Badar A; Balasubramanian K; Lohiya NK
    Asian J Androl; 2017; 19(4):389-395. PubMed ID: 27586026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contraception in male monkeys by intra-vas deferens injection of a pH lowering polymer.
    Guha SK; Ansari S; Anand S; Farooq A; Misro MM; Sharma DN
    Contraception; 1985 Jul; 32(1):109-18. PubMed ID: 4053602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biophysical mechanism-mediated time-dependent effect on sperm of human and monkey vas implanted polyelectrolyte contraceptive.
    Guha SK
    Asian J Androl; 2007 Mar; 9(2):221-7. PubMed ID: 17334590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Injectable non-occlusive chemical contraception in the male-I.
    Misro M; Guha SK; Singh H; Mahajan S; Ray AR; Vasudevan P
    Contraception; 1979 Nov; 20(5):467-73. PubMed ID: 43211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RISUG
    Khilwani B; Badar A; Ansari AS; Lohiya NK
    Basic Clin Androl; 2020; 30():2. PubMed ID: 32082579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I clinical trial of an injectable contraceptive for the male.
    Guha SK; Singh G; Anand S; Ansari S; Kumar S; Koul V
    Contraception; 1993 Oct; 48(4):367-75. PubMed ID: 8222664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Smart RISUG: a potential new contraceptive and its magnetic field-mediated sperm interaction.
    Jha RK; Jha PK; Guha SK
    Int J Nanomedicine; 2009; 4():55-64. PubMed ID: 19421370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sperm characteristics and teratology in rats following vas deferens occlusion with RISUG and its reversal.
    Lohiya NK; Suthar R; Khandelwal A; Goyal S; Ansari AS; Manivannan B
    Int J Androl; 2010 Feb; 33(1):e198-206. PubMed ID: 19811546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety evaluation through genotoxicity and apoptotic markers following RISUG
    Ansari AS; Badar A; Lohiya NK
    Reprod Toxicol; 2018 Oct; 81():84-92. PubMed ID: 30036573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vas deferens, a site of male contraception: an overview.
    Lohiya NK; Manivannan B; Mishra PK; Pathak N
    Asian J Androl; 2001 Jun; 3(2):87-95. PubMed ID: 11404791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.